Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

- To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)

- The feasibility will be evaluated in terms of objective response rate, efficacy of stem cell collection, disease-free survival, and overall survival.

Inclusion Criteria:

• Patients who have refractory to first-line CHOP-like regimen
• Patients who have first relapse after
• first-line CHOP-like regimen
• upfront autologous or allogeneic hematopoietic stem cell transplantation
• Age 15 years or more
• ECOG performance status ≤ 2
• Adequate bone marrow function
• Adequate kidney,liver,cardiac

Exclusion Criteria:

• Patients who have received GEM or OX